Skip to main content

SomaLogic and Archemix Divide Aptamer Patent Estate

NEW YORK, Sept. 24 (GenomeWeb News) - SomaLogic has signed on to an IP alliance with Archemix, a biopharma based in Cambridge, Mass., for use of aptamers in diagnosis and therapeutics, the companies said Tuesday.


Under the agreement, SomaLogic, of Boulder, Colo., will have exclusive rights to diagnostics and ex vivo detection applications of aptamer technology, while Archemix has rights to therapeutics based on aptamers. For drug screening and target validation, the companies will cross-license the technologies.


The companies have also agreed to jointly "maintain , expand, and defend the aptamer patent estate," which includes over 150 patents and 100 patent applications, according to a press statement.


Aptamers are single-stranded nucleic acids will three-dimensional shapes that enable them to bind specifically to target molecules with high affinity.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.